HIV treatment and prevention on every 2026 Oklahoma Part D plan
Pick a drug class, or type the drugs you want to check, and see which of the 11 stand-alone Part D plans in Oklahoma cover each one, on what tier, and with what restrictions.
- Covered
- Covered, needs prior authorization (PA) or step therapy (ST)
- Not on the formulary
- QL 60/30d = quantity limit, 60 units per 30 days
11 plans, cheapest premium first. Scroll sideways for all of them →
| Drug | Blue Cross MedicareRx Basic$0.00/moS5715-015 | Humana Basic Rx Plan$0.00/moS5884-144 | Wellcare Value Script$5.60/moS4802-156 | Wellcare Classic$5.70/moS4802-014 | Humana Value Rx Plan$33.70/moS5884-202 | HealthSpring Extra Rx$65.40/moS5617-373 | AARP Medicare Rx Saver from UHC$82.40/moS5921-368 | Humana Premier Rx Plan$108.60/moS5884-169 | AARP Medicare Rx Preferred from UHC$121.00/moS5921-404 | HealthSpring Assurance Rx$126.50/moS5617-113 | Blue Cross MedicareRx Value$167.30/moS5715-010 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Biktarvybictegravir/emtricitabine/tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 525% | Tier 525%QL 30/30d |
| Dovatodolutegravir and lamivudine | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 525% | Tier 525%QL 30/30d |
| Triumeqabacavir/dolutegravir/lamivudine | Tier 440%QL 180/30d | Tier 429%QL 180/30d | Tier 440% | Tier 426% | Tier 435%QL 180/30d | Tier 430%QL 300/30d | Tier 441%QL 180/30d | Tier 450%QL 180/30d | Tier 440%QL 180/30d | Tier 429%QL 300/30d | Tier 432%QL 180/30d |
| Genvoyaelvitegravir/cobicistat/emtricitabine/tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d |
| Odefseyemtricitabine/rilpivirine/tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d |
| Symtuzadarunavir/cobicistat/emtricitabine/tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 525% | Tier 525%QL 30/30d |
| Julucadolutegravir and rilpivirine | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525% | Tier 525% | Tier 526%QL 30/30d | Tier 525% | Tier 525%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 525% | Tier 525%QL 30/30d |
| Descovyemtricitabine and tenofovir alafenamide | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 526%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d | Tier 533%QL 30/30d | Tier 531%QL 30/30d | Tier 525%QL 30/30d | Tier 525%QL 30/30d |
| Truvadaemtricitabine and tenofovir disoproxil | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered | Not covered |
| emtricitabine-tenofovirgeneric Truvada | Tier 440%QL 30/30d | Tier 429%QL 30/30d | Tier 440%QL 30/30d | Tier 426%QL 30/30d | Tier 435%QL 30/30d | Tier 430%QL 30/30d | Tier 441%QL 30/30d | Tier 450%QL 30/30d | Tier 440%QL 30/30d | Tier 429%QL 30/30d | Tier 432%QL 30/30d |
| Tivicaydolutegravir | Tier 525%QL 60/30d | Tier 525%QL 60/30d | Tier 525% | Tier 525% | Tier 526%QL 60/30d | Tier 430%QL 180/30d | Tier 525%QL 60/30d | Tier 533%QL 60/30d | Tier 531%QL 60/30d | Tier 429%QL 180/30d | Tier 525%QL 60/30d |
Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.